Technical Analysis for LABP - Landos Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Support | Bullish | 1.10% | |
| Bollinger Band Squeeze | Range Contraction | 1.10% | |
| Earnings Movers | Other | 1.10% | |
| Bollinger Band Squeeze | Range Contraction | 0.54% | |
| Three Weeks Tight | Range Contraction | 0.54% | |
| Earnings Movers | Other | 0.54% | |
| Gapped Down | Weakness | 0.54% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 7 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
| 10 DMA Support | about 8 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Gapped Up (Full) | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.84 |
| 52 Week Low | 2.5 |
| Average Volume | 27,441 |
| 200-Day Moving Average | 7.61 |
| 50-Day Moving Average | 17.65 |
| 20-Day Moving Average | 22.19 |
| 10-Day Moving Average | 22.26 |
| Average True Range | 0.37 |
| RSI (14) | 80.73 |
| ADX | 74.89 |
| +DI | 42.48 |
| -DI | 7.34 |
| Chandelier Exit (Long, 3 ATRs) | 21.74 |
| Chandelier Exit (Short, 3 ATRs) | 22.53 |
| Upper Bollinger Bands | 22.63 |
| Lower Bollinger Band | 21.74 |
| Percent B (%b) | 0.79 |
| BandWidth | 4.01 |
| MACD Line | 1.07 |
| MACD Signal Line | 1.44 |
| MACD Histogram | -0.3661 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.95 | ||||
| Resistance 3 (R3) | 22.93 | 22.76 | 22.86 | ||
| Resistance 2 (R2) | 22.76 | 22.63 | 22.76 | 22.83 | |
| Resistance 1 (R1) | 22.60 | 22.55 | 22.52 | 22.62 | 22.81 |
| Pivot Point | 22.43 | 22.43 | 22.38 | 22.43 | 22.43 |
| Support 1 (S1) | 22.27 | 22.30 | 22.19 | 22.29 | 22.09 |
| Support 2 (S2) | 22.10 | 22.22 | 22.10 | 22.07 | |
| Support 3 (S3) | 21.94 | 22.10 | 22.04 | ||
| Support 4 (S4) | 21.96 |
